Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database
| Autor: | Christian Chidiac, R. Allard, Patrick Miailhes, Philippe Chevallier, C. Trepo, Jacques Ritter, Dominique Peyramond, Jean-Michel Livrozet, J. Fabry, Nicolas Voirin, Philippe Vanhems, Jean-Louis Touraine |
|---|---|
| Přispěvatelé: | Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty [SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT] Hepatitis C virus HIV Infections medicine.disease_cause Cohort Studies 03 medical and health sciences 0302 clinical medicine immune system diseases Virology Internal medicine Antiretroviral Therapy Highly Active Epidemiology medicine Humans 030212 general & internal medicine Substance Abuse Intravenous Survival analysis Hepatology biology business.industry Incidence (epidemiology) Mortality rate virus diseases Hepatitis C Hepatitis C Antibodies medicine.disease Survival Analysis 3. Good health Infectious Diseases Immunology biology.protein Disease Progression 030211 gastroenterology & hepatology Female France Antibody business Cohort study |
| Zdroj: | Journal of Viral Hepatitis Journal of Viral Hepatitis, Wiley-Blackwell, 2004, 11, pp.559-562 Journal of Viral Hepatitis, 2004, 11, pp.559-562 |
| ISSN: | 1352-0504 1365-2893 |
| Popis: | Highly active antiretroviral therapy (HAART) has reduced the incidence of death in HIV-infected patients but various rates of survival have been reported due to the infection with hepatitis C virus (HCV) and the use of injecting drugs (IDU). A survival analysis was performed to estimate and compare the death rates in HIV-positive patients infected by IDU and/or positive for HCV antibodies in the pre-HAART and HAART periods in Lyon (France) between 1992 and 2002. Patients were stratified into four groups (G): HCV-/IDU-(G1), HCV+/IDU-(G2), HCV+/IDU-(G3), HCV+/IDU+ (G4) and adjusted death rates in the pre-HAART era (1996) and the HAART era (or = 1996) were compared. The aHR of progression to death was 1.05 (95% CI 0.75-1.47, P = 0.75) for G2, 1.09 (95% CI 0.54-2.22, P = 0.81) for G3 and 0.90 (95% CI 0.65-1.24, P =0.51) for G4 compared with G1 in the pre-HAART era. The aHR of progression to death was 0.76 (95% CI 0.28-2.08, P = 0.59) for G2, 1.23 (95% CI 0.17-8.86, P = 0.84) for G3 and 2.90 (95% CI 1.62-5.20, P0.001) for G4, compared with G1 in the HAART era. HAART management of HCV+/IDU+ patients needs to be optimized for them to achieve a similar benefit as observed among other individuals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text